Hualing Pharmaceutical (02552.HK) 2024 Interim Report Review: Huatangning accelerates admission to the hospital for the second generation and progresses smoothly in overseas clinical trials

Sep 2, 2024 21:01

Hualing Pharmaceutical-B (2552.HK): The orderly promotion of commercialization of Huatang Ning has received a milestone payment of 1.5 billion yuan

Sep 18, 2023 00:00

Hualing Pharmaceutical-B (2552.HK): Exclusive varieties combined with MNC to help commercialize the Nuggets oral hypoglycemic drug market

太平洋證券Sep 7, 2023 00:00

Hualing Pharmaceutical-B (2552.HK) Company Review: The milestones of 23H1 have borne fruit and continued to promote Huatangning's sales

華安證券Aug 29, 2023 12:02

Hualing Pharmaceutical (2552.HK): Huatang Ning received another milestone payment to actively prepare for national health insurance talks

華安證券Aug 21, 2023 15:22

Hualing Pharmaceutical (02552.HK): Huatangning successfully initially commercialized and actively expanded R&D pipelines

東方財富證券Apr 13, 2023 18:12

Goldman Sachs: Huatangning's sales growth shows positive signs for Hualing Pharmaceutical's “buy” rating and target price of HK$7.53

Gelonghui FinanceApr 3, 2023 10:50

Hualing Pharmaceutical-B (02552.HK) Dynamic Review: Huatangning, the world's first innovative drug, glucokinase activator, was approved for marketing

東方財富證券Oct 12, 2022 13:06

Hualing Pharmaceutical-B (02552.HK): Ten years have passed, and the first oral drug for type 2 diabetes, dogliadin, will soon be approved for marketing

東方財富證券Jul 27, 2022 12:46